Document Detail

Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy.
MedLine Citation:
PMID:  15539124     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A toxic and pro-oxidative effect of homocysteine on the coronary endothelium may accelerate cardiac allograft vascular disease (CAVD). In this study, we evaluated the influence of hyperhomocysteinemia on the course of CAVD. METHODS: We investigated plasma homocysteine (tHCY) concentrations in 183 consecutive heart transplant recipients (158 men and 25 women, mean aged 53.1 +/- 10.0 years, at 6.7 +/- 3.2 years after transplantation) to evaluate the course of CAVD. We used serial coronary angiography to assess coronary status and graded the severity of CAVD based on the extent of luminal obstruction in the main coronary arteries (graded as 1-4). We defined progression as increased focal stenosis of >/=30% or as detection of a new coronary lesion after a mean observation period of 2.8 +/- 1.0 years. A multivariate analysis (backward logistic regression) was performed that included potential risk factors for CAVD. We excluded patients undergoing dialysis. RESULTS: Initially, tHCY concentrations were increased in the entire cohort (mean, 18.6 +/- 7.6 mumol/liter) and ranged from 6.6 to 46.9 mumol/liter. A total of 105 patients (57.0%) had CAVD at first angiography, and progression was detected in 52 transplant recipients (28.0%). Patients with progressive CAVD had significantly greater tHCY concentrations (21.6 +/- 6.2 mumol/liter) at baseline investigation compared with patients who had stable courses (17.4 +/- 7.7 mumol/liter; p < 0.001). These results were independent of parameters such as sex, age, dyslipoproteinemia, cyclosporine blood concentrations, and indication for transplantation. CONCLUSIONS: Progression of CAVD is strongly associated with increased tHCY concentrations. The intervals between routine surveillance angiography should be shortened in patients with hyperhomocysteinemia, and routine medical treatment to decrease homocysteine concentrations should be considered.
Ingo Kutschka; Klaus Pethig; Wolfgang Harringer; Axel Haverich; Martin Strüber;
Related Documents :
16028464 - Prediction of coronary artery disease severity in patients referred for coronary angiog...
24775894 - Prognostic value of noninvasive markers of coronary reperfusion compared to timi 3 flow...
23465094 - Peak and fixed-time high-sensitive troponin for prediction of infarct size, impaired le...
23494604 - Impact of advanced age on myocardial perfusion, distal embolization, and mortality pati...
18515284 - Antibodies with beta-adrenergic activity from chronic chagasic patients modulate the qt...
18360184 - The role of fish oil in arrhythmia prevention.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  23     ISSN:  1053-2498     ISO Abbreviation:  J. Heart Lung Transplant.     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-11-12     Completed Date:  2005-07-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1260-5     Citation Subset:  IM    
Department of Thoracic and Cardiovascular Surgery, Klinikum Braunschweig, Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / blood*,  etiology*
Disease Progression
Heart Transplantation / adverse effects*
Homocysteine / blood*
Middle Aged
Risk Factors
Time Factors
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Donor-recipient gender mismatch in lung transplantation: impact on obliterative bronchiolitis and su...
Next Document:  alpha4beta1-integrin blockade and cyclosporine decreases the prevalence and severity of transplant v...